TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study

TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation study

Abstract Functional loss of the intracellular peptide Transporter associated with Antigen Processing (TAP) fosters resistance to T-cell based immunotherapy. We discovered the presentation of an alternative set of shared tumor antigens on such escaped cancers and developed a LRPAP1 synthetic long pep...

Full description

Saved in:
Bibliographic Details
Main Authors: Mitchell Emmers, Marij J. P. Welters, Michelle V. Dietz, Saskia J. Santegoets, Sanne Boekesteijn, Anouk Stolk, Nikki M. Loof, Daphne W. Dumoulin, Annemarie L. Geel, Lauri C. Steinbusch, A. Rob P. M. Valentijn, Danielle Cohen, Noel F. C. C. de Miranda, Egbert F. Smit, Hans Gelderblom, Thorbald van Hall, Joachim G. Aerts, Sjoerd H. van der Burg
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-60281-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-60281-8

Similar Items